Gynecologic Oncology Reports最新文献

{"title":"The effect of intrawound vancomycin powder on surgical site infection in inguinal lymph node dissection: a randomized controlled trial pilot study","authors":"Jessica B. DiSilvestro ,&nbsp;Emily Zitek ,&nbsp;Katina Robison ,&nbsp;Jasmine Ebott ,&nbsp;Corinne Jansen ,&nbsp;Katrin Eurich ,&nbsp;Cara Mathews ,&nbsp;Paul DiSilvestro ,&nbsp;Matthew Oliver ,&nbsp;Ashley Stuckey ,&nbsp;Katherine Miller ,&nbsp;Elizabeth Lokich","doi":"10.1016/j.gore.2025.101765","DOIUrl":"10.1016/j.gore.2025.101765","url":null,"abstract":"<div><h3>Background</h3><div>Inguinal lymph node dissections are morbid surgeries with high rates of postoperative wound infections. The primary objective of this pilot study was to assess the feasibility of implementing a randomized controlled trial to assess the impact of intrawound vancomycin powder on postoperative complications after inguinal lymph node dissection in patients with vulvar cancer. Secondary objectives included 1) 30-day composite postoperative complication rate, and 2) adverse effects.</div></div><div><h3>Methods</h3><div>This was a single-site, unblinded randomized controlled trial. Patients with vulvar cancer planning to undergo an inguinal lymph node dissection were randomized 1:1 to receive intrawound vancomycin powder at the time of surgery versus standard of care without vancomycin powder. Descriptive statistics and Chi-square were utilized.</div></div><div><h3>Results</h3><div>Between October 2022 to May 2024, 31 patients met eligibility criteria and 30 patients enrolled (97 % recruitment rate). Three patients did not undergo surgery (90 % retention rate). All patients received their correctly assigned arm and all patients completed the postoperative follow-up (100 % adherence rate).</div><div>One patient in the vancomycin group had a composite postoperative complication (hematoma), while three patients in the control arm had a complication (three inguinal surgical site infections) [8 % vs. 21 %, p = 0.32]. There were no postoperative infections identified in the patients who received intrawound vancomycin powder. No adverse events occurred with the application of vancomycin.</div></div><div><h3>Conclusion</h3><div>This pilot study showed that this was a feasible trial with high recruitment, retention and adherence rates. The data supports proceeding with a larger trial to further elucidate the impact of this low-cost intervention.</div><div>Trial Registration: ClinicalTrials.gov Identifier: NCT05625373.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101765"},"PeriodicalIF":1.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of intravenous leiomyomatosis: a case report illustrating two distinct surgical approaches","authors":"Michal Moshkovich ,&nbsp;Emily Volfson ,&nbsp;Robert J. Cusimano ,&nbsp;Miranda Witheford ,&nbsp;Marcus Q. Bernardini ,&nbsp;Johannes Koen ,&nbsp;Rachel Soyoun Kim","doi":"10.1016/j.gore.2025.101762","DOIUrl":"10.1016/j.gore.2025.101762","url":null,"abstract":"<div><div>Intravenous leiomyomatosis (IVL) is a benign smooth muscle growth originating in the uterus that extends into the lumen of venous or lymphatic vessels beyond the myoma. The tumour may enter the inferior vena cava (IVC) or the heart. For IVL with cardiac involvement, two distinct surgical approaches may be considered. The conventional approach involves concurrent intracardiac tumour resection via sternotomy, and resection of the intrabdominal/pelvic tumour by laparotomy, incision into the IVC, and a hysterectomy. Alternatively, an abdominal-only approach allows complete resection of the cardiac, abdominal, and pelvic portions of the IVL through IVC incision and hysterectomy. Considerations for surgical timing include a single-stage procedure, where all tumour components are addressed in one operation, or two-stage procedures, where cardiac and abdominal/pelvic components are resected in separate operations. Both approaches carry specific risks and benefits for the surgical course and patient recovery. We report two cases of patients presenting with symptomatic IVL. Patient A underwent a single-stage abdominal-only approach, including tumour removal from the IVC and hysterectomy, while Patient B underwent a two-stage surgical course involving initial intracardiac tumour resection via sternotomy, followed by a delayed subsequent abdominal tumour resection. We discuss the clinical decision-making process, benefits, and risks of both approaches, as well as preoperative and postoperative management considerations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101762"},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal compartment syndrome and mixed germ cell tumor: A case of multidisciplinary management and long-term disease-free survival","authors":"Natalie L. Ayoub ,&nbsp;Rebecca Shin ,&nbsp;Patrick Peñalosa ,&nbsp;Marisa Liu ,&nbsp;Lourdes Swentek ,&nbsp;Jill Tseng","doi":"10.1016/j.gore.2025.101759","DOIUrl":"10.1016/j.gore.2025.101759","url":null,"abstract":"<div><h3>Introduction</h3><div>Abdominal compartment syndrome is a life-threatening condition caused by elevated intra-abdominal pressure. The most common causes of abdominal compartment syndrome include trauma, burns, and acute pancreatitis. Gynecologic etiologies rarely cause abdominal compartment syndrome, especially in the setting of tumor rupture or hemorrhage. We present an unusual presentation of abdominal compartment syndrome and associated posterior reversible encephalopathy syndrome (PRES) caused by a ruptured mixed germ cell tumor.</div></div><div><h3>Case Description</h3><div>A 26-year-old female presented with abdominal pain, a large abdominopelvic mass measuring 15 × 22 × 27 cm and elevated tumor markers concerning for an ovarian germ cell tumor. During admission, the patient developed hemodynamic instability, PRES, acute kidney injury, and elevated intravesical pressure consistent with abdominal compartment syndrome. She underwent emergent surgical decompression with an exploratory laparotomy, tumor debulking, and unilateral oophorectomy. Final pathology confirmed stage IIIC1 mixed germ cell tumor. Postoperatively, she received six cycles of bleomycin, etoposide, and cisplatin therapy (BEP). She has remained disease-free since completion of treatment, now totaling three years.</div></div><div><h3>Discussion</h3><div>This case demonstrates a rare presentation of a newly diagnosed ovarian malignancy and highlights the rapid decompensation of patients with abdominal compartment syndrome. Acute surgical intervention is critical for survival, and prioritization of patient stability over extensive debulking reflects the nuanced intraoperative decision-making that is required in high-risk scenarios.</div></div><div><h3>Conclusion</h3><div>Early recognition and coordination of care are important in effectively managing compartment syndrome in patients with gynecologic malignancies. Although uncommon, abdominal compartment syndrome should remain in the differential diagnosis for patients with acute decompensation and a large abdominopelvic mass.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101759"},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143929595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on cancer recurrence rates in patients with ovarian cancer","authors":"Amrita Mukherjee ,&nbsp;Natalie Ayoub ,&nbsp;Lanfang Xu ,&nbsp;Kimberly L. Cannavale ,&nbsp;Alec D. Gilfillan ,&nbsp;Elizabeth A. Szamreta ,&nbsp;Matthew J. Monberg ,&nbsp;Melissa Hodeib ,&nbsp;Chun R. Chao","doi":"10.1016/j.gore.2025.101763","DOIUrl":"10.1016/j.gore.2025.101763","url":null,"abstract":"<div><div>The coronavirus diseases 2019 (COVID-19) pandemic was associated with disruption of oncology care and increased utilization of telehealth. However, the impact of the pandemic on cancer outcomes is under-studied. We evaluated the impact of the COVID-19 pandemic on recurrence rates in ovarian cancer patients in a retrospective cohort study. Women (age ≥ 18 years) diagnosed with stage I-IV epithelial ovarian cancer between 01/01/2017–06/30/2021 at Kaiser Permanente Southern California who received chemotherapy and/or surgery; and achieved complete remission following first-line treatment were included. The pre-pandemic and pandemic periods were defined based on the date of implementation of stay-at-home order in California (03/04/2020). Chart reviews were conducted to determine recurrence within 12 months of remission by physician notes, imaging findings, or CA125 levels. A total of 548 patients were included; 73.4 % and 26.6 % patients were diagnosed during the pre-pandemic and pandemic periods, respectively. About a quarter of the patients had cancer recurrence within 12 months of remission; 25.6 % and 19.2 % of patients diagnosed in the pre-pandemic and pandemic periods had recurrence, respectively (p-value = 0.12). Patients diagnosed during the pandemic were 35 % less likely to have recurrence than those in the pre-pandemic period, after adjusting for age, race/ethnicity, cancer stage, and time to treatment. Additionally adjusting for poly-ADP ribose polymerase (PARP) inhibitors in patients with stage II-IV cancer led to similar findings. In conclusion, ovarian cancer patients diagnosed and treated during the COVID-19 pandemic at KPSC did not have a higher recurrence rate than patients in the pre-pandemic period, despite changes in management approach.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101763"},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond GOG258 and PORTEC3: A National Cancer Database analysis of adjuvant therapy for improved survival in high-risk endometrial cancer","authors":"Megan E Lander ,&nbsp;John Vargo ,&nbsp;Runjia Li ,&nbsp;G.K. Balasubramani ,&nbsp;Ron Buckanovich ,&nbsp;Jamie Lesnock ,&nbsp;Alison Garrett ,&nbsp;Shannon Rush ,&nbsp;Paniti Sukumvanich","doi":"10.1016/j.gore.2025.101756","DOIUrl":"10.1016/j.gore.2025.101756","url":null,"abstract":"<div><h3>Purpose</h3><div>High-risk Endometrial Cancer (EC) treatment decisions have been informed by two large, randomized trials: GOG-258 and PORTEC-3. Directly comparing these studies to determine the optimal treatment strategy remains challenging as neither included all three arms of interest: chemotherapy alone, chemotherapy combined with radiation, and radiation therapy alone. This study addresses this gap by analyzing National Cancer Database (NCDB) data to evaluate the comparative effectiveness of chemotherapy alone, chemoradiotherapy, and radiation therapy alone.</div></div><div><h3>Methods</h3><div>The NCDB was queried for patients with stage II-IVa endometrioid and any stage clear cell or serous EC who underwent primary surgery with hysterectomy between 2004 and 2020. Univariable and multivariable models investigated prognostic factors and overall survival. Propensity weighted analysis adjusted for potential indication bias.</div></div><div><h3>Results</h3><div>48,831 patients met inclusion criteria. 19,251 received no adjuvant treatment, 8,076 received adjuvant radiation only, 13,418 received adjuvant chemotherapy only, 1,849 received adjuvant concurrent chemoradiation, and 6,237 received adjuvant sequential chemotherapy and radiation. Factors independently associated with improved survival included adjuvant treatment modality, age, race, insurance status, histology, grade, stage, facility type, facility location, and residential setting. Multivariate propensity weighted analysis showed concurrent and sequential chemoradiation significantly improved OS (HR 0.69, 95 % CI 0.0.60–0.80, p &lt; 0.001; HR 0.63, 95 % CI 0.59–0.67, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Chemoradiation is associated with improved OS in high-risk EC patients regardless of various factors. This data suggests chemoradiation as a preferred treatment option, however, prospective trials directly comparing chemotherapy, radiation, and chemoradiation are needed for confirmation.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101756"},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer","authors":"Katsuaki Inami","doi":"10.1016/j.gore.2025.101761","DOIUrl":"10.1016/j.gore.2025.101761","url":null,"abstract":"<div><h3>Objective</h3><div>To review the cost-effectiveness of chemotherapy and immunotherapy-based regimens for advanced and recurrent endometrial cancer, focusing on incremental cost-effectiveness ratios (ICERs).</div></div><div><h3>Methods</h3><div>We conducted a literature review of peer-reviewed studies (2021–2025) evaluating immune checkpoint inhibitors (ICIs) combined with chemotherapy or targeted agents versus standard chemotherapy in advanced/recurrent endometrial cancer. Key outcomes (cost per QALY or life-year gained, willingness-to-pay [WTP] thresholds) and conclusions were extracted from nine studies.</div></div><div><h3>Results</h3><div>Adding ICIs to first-line chemotherapy improved survival, especially in mismatch repair-deficient (dMMR) tumors. In dMMR disease, pembrolizumab or dostarlimab plus chemotherapy yielded ICERs of $41,000–$60,000/QALY, considered cost-effective at a $150,000/QALY threshold, but not at $100,000/QALY without price reductions. In mismatch repair-proficient (pMMR) patients, first-line ICI combinations showed smaller QALY gains and higher ICERs ($90,000–$176,000/QALY), often exceeding accepted thresholds. The durvalumab + olaparib combination was not cost-effective in any subgroup (ICERs &gt;$200,000/QALY). In recurrent pMMR disease, pembrolizumab + lenvatinib was not cost-effective in U.S. or Chinese settings unless drug costs declined by 8–50 %. In recurrent dMMR cancer, dostarlimab improved outcomes but had an ICER of $332,000/QALY, making it economically unjustified at current prices.</div></div><div><h3>Conclusions</h3><div>ICIs offer clinical benefit in advanced endometrial cancer, particularly in dMMR tumors. First-line ICI + chemotherapy appears cost-effective for dMMR at U.S. WTP levels. However, use in pMMR or second-line settings may require drug price reductions or biomarker-based selection to be economically viable.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101761"},"PeriodicalIF":1.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic review","authors":"Mahalia Huba ,&nbsp;Fahad Hussain ,&nbsp;Saimanoj Guntaka ,&nbsp;Awais Paracha ,&nbsp;Pranav Sathe ,&nbsp;Bhavya Parikh ,&nbsp;Margot Noyelle ,&nbsp;Umar Durrani ,&nbsp;Himanshu Patel ,&nbsp;Veena John","doi":"10.1016/j.gore.2025.101751","DOIUrl":"10.1016/j.gore.2025.101751","url":null,"abstract":"<div><h3>Background</h3><div>Non-Bacterial Thrombotic Endocarditis (NBTE) is characterized by the formation of sterile vegetations on the heart valves, often due to an underlying hypercoagulable state in the setting of malignancy, inflammation, or autoimmune disease. NBTE is a rare condition with a reported incidence rate of between 0.9% and 1.6%. Among gynecologic malignancies, NBTE is predominantly observed in ovarian cancer. A comprehensive review of the literature was conducted to understand the association between NBTE and ovarian cancer.</div></div><div><h3>Methods</h3><div>A search of PubMed/MEDLINE was conducted from database inception to January 2024 using terms related to “Non-Bacterial Thrombotic Endocarditis” and “Ovarian Cancer.” Studies were included if they involved patients diagnosed with both NBTE and ovarian cancer and excluded if they did not report confirmed NBTE and ovarian cancer. Risk of bias was assessed using Mixed Methods Analysis Testing.</div></div><div><h3>Results</h3><div>The search identified 15 patients from 14 case reports, all female, with an average age of 50.6. The most common presenting diagnosis was CVA (53%). Ovarian cancer was diagnosed before NBTE 57% of the time. Most patients (67%) had stage III or IV cancer. Metastases predominantly affected lymph nodes (40%), liver (40%), and the other ovary (20%). Malignancy was treated with chemotherapy in 63% of cases. Surgical resection was performed in 40% of cases. One patient underwent radiation therapy. Mortality rate was 40% in patients treated with chemotherapy and 100% in patients not receiving chemotherapy. NBTE predominantly affected the mitral valve (52.4%), followed by the aortic valve at (33.3%), and the tricuspid valve (14.3%). 80% of patients experienced organ infarct. Infarcts predominantly affected the brain (27.0%), spleen (27.0%), lung (8.1%), and heart (8.1%). NBTE was treated with anticoagulation in 54% of cases. All-cause mortality at study publication was 75%.</div></div><div><h3>Conclusions</h3><div>NBTE is an important, and often overlooked, cause of mortality in ovarian cancer. Clinicians should maintain high clinical suspicion for NBTE in patients with ovarian cancer presenting with thromboembolic phenomena.</div></div><div><h3>REGISTRATION</h3><div>This review was registered with PROSPERO under the ID number: CRD42024501301.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101751"},"PeriodicalIF":1.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report","authors":"Dalila Incognito ,&nbsp;Massimiliano Berretta ,&nbsp;Giosuè Giordano Incognito ,&nbsp;Ferdinando Antonio Gulino ,&nbsp;Roberta Foti ,&nbsp;Vincenzo Canzonieri ,&nbsp;Claudia Gelsomino ,&nbsp;Marco Palumbo ,&nbsp;Antonio Picone","doi":"10.1016/j.gore.2025.101754","DOIUrl":"10.1016/j.gore.2025.101754","url":null,"abstract":"<div><div>Vulvar Paget’s disease (VPD) is a rare intraepithelial malignancy frequently associated with HER2 overexpression. This study offers insights into managing HER2-positive extramammary Paget’s disease cases in which trastuzumab monotherapy was administered as manteinance therapy. We report the case of a 52-year-old woman with VDP and lymph node involvement, who was initially treated with paclitaxel and trastuzumab, for which chemotherapy was discontinued due to significant side effects, and trastuzumab as maintenance therapy was continued, resulting in significant regression of metastatic lesions. Additionally, a systematic review was conducted. The review included 6 studies from 2008 to 2020. Complete response was achieved in 2 out of 7 (28.6%) cases, partial response in 4 (42.9%) cases, and stable disease in 1 (14.3%) case. Mild moderate headache and flushing during trastuzumab manteinance therapy were reported in only one patient. In conclusion, trastuzumab monotherapy may be a valid alternative option, particularly in patients unable to tolerate combination chemotherapy. These findings emphasize the importance of personalized treatment approaches.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101754"},"PeriodicalIF":1.2,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance of intraoperative cytology with frozen section and final pathology for ovarian neoplasms","authors":"Jacqueline Early ,&nbsp;Gagandeep Kaur ,&nbsp;Lisa Arrigo ,&nbsp;Skylar Gill ,&nbsp;Mary Chacho ,&nbsp;Paul Fiedler ,&nbsp;Linus Chuang","doi":"10.1016/j.gore.2025.101757","DOIUrl":"10.1016/j.gore.2025.101757","url":null,"abstract":"<div><h3>Introduction</h3><div>Intraoperative frozen section analysis (IOFS) is a widely used method for evaluating ovarian masses and guiding surgical decisions. However, IOFS is not always accessible in low-resource settings. Recent research suggests that intraoperative cytology (IOC) may offer a quicker, less equipment-dependent alternative. This study aims to compare IOC and IOFS in women with ovarian neoplasms. The pathologists interpreting IOC were blinded to IOFS findings.</div></div><div><h3>Methods</h3><div>The study included 15 women aged 18 or older undergoing surgery for ovarian mass removal. Patients with biopsy-confirmed malignancies or known recurrences were excluded. After tumor removal, both IOFS and IOC were performed. IOFS involved using a Cryostat for sectioning and H&amp;E staining. IOC used touch/imprint, scrape, and crush techniques. Independent pathologists analyzed the smears, and paraffin-embedded tissue histopathology was the diagnostic gold standard.</div></div><div><h3>Results</h3><div>IOC results were consistent with final pathology in 10 of 15 cases, while IOFS matched in 12 cases. IOC had 4 indeterminate and 1 borderline diagnosis, compared to 1 indeterminate, 1 benign, and 1 borderline diagnosis with IOFS. Three discrepancies between IOC and IOFS were identified, with IOC providing indeterminate results where IOFS ranged from benign to malignant. Indeterminate cases led to malignancy management strategies, including intraoperative staging.</div></div><div><h3>Conclusion</h3><div>This pilot study indicates that intraoperative cytology is a practical and effective method for rapid ovarian neoplasm evaluation. Further research with larger cohorts is needed to assess its comparative performance with frozen section analysis and optimize its methodology. IOC may offer a viable option for intraoperative surgical guidance.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101757"},"PeriodicalIF":1.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bricker ileal conduit diversion with ICG technique in 10 steps","authors":"Clara Dujardin ,&nbsp;Fabrice Narducci ,&nbsp;Delphine Hudry ,&nbsp;Arnaud Villers ,&nbsp;Gautier Marcq ,&nbsp;Carlos Martinez Gomez","doi":"10.1016/j.gore.2025.101753","DOIUrl":"10.1016/j.gore.2025.101753","url":null,"abstract":"<div><div>The Bricker ileal conduit is a widely used incontinent urinary diversion, commonly performed after pelvic exenteration. Described by Bricker in 1950 (<span><span>Bricker, 1950</span></span>), it remains popular due to low complication rates and surgical simplicity (<span><span>Martínez-Gómez et al., 2021</span></span>). Early postoperative complications include intestinal or urinary fistulas, while late ones involve ureteral stenosis (<span><span>Hétet et al., 2005</span></span>).</div><div>In women’s cancers, pelvic exenteration often follows radiotherapy or retroperitoneal dissection during aortic lymphadenectomy, involving extensive left-sided ureteral dissection, which complicates ureteral vascularization.</div><div>ICG (indocyanine green) is a safe, widely used technique in oncologic surgery to assess tissue vascularization, reducing fistula and stenosis risks in ileoureteral and ileoileal anastomoses.</div><div>The urinary conduit is made from a 20 cm ileal segment, with ureters anastomosed separately to the proximal end. ICG is injected intravenously to assess ureteral and anastomotic vascularization. The distal end forms a cutaneous stoma.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101753"},"PeriodicalIF":1.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}